Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pantoprazole

- PMLiVE

A new option for people with HIV

ViiV Healthcare's dolutegravir could capture a significant share of the HIV market and may have blockbuster potential

- PMLiVE

Pfizer beats earnings estimates as new products grow

Lyrica, Inlyta and Xalkori help offset generic competition

- PMLiVE

CHMP turns down drugs for MS, cancer and muscular dystrophy

Negative EU recommendations for Teva, AB Science and PTC Therapeutics

- PMLiVE

Blow to Pfizer as dacomitinib fails in lung cancer trials

Unable to demonstrate improved survival in patients

- PMLiVE

ViiV wins European approval for Tivicay

HIV treatment licensed in combination with other anti-retroviral drugs

- PMLiVE

Actavis sells EU generics businesses to Aurobindo

Divests operations in seven Western European countries

- PMLiVE

Teva names Vigodman CEO and makes bid for NuPathe

Israeli pharma company confirms Jeremy Levin’s replacement

- PMLiVE

Key Teva shareholder backs Vigodman as next CEO

Board director tipped to replace Jeremy Levin at Israeli pharma firm

- PMLiVE

AZ faces early competition to Nexium in the US

Korea's Hanmi and Amneal Pharmaceuticals launches first generic rival

- PMLiVE

Teva’s vice chair steps down

Amir Elstein to take over from Moshe Many

Pfizer’s Jonathan Emms to be ABPI president

Will take over from MSD's Deepak Khanna in April

- PMLiVE

Pfizer ups the ante on clinical transparency

Revamps access to data portal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links